Compare Eli Lilly And Co (LLY) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.46 (market cap $73.20B). The key difference: Eli Lilly And Co is far larger — about 14.2× Vanguard Sht-Term Inflation-Protected Sec Idx ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| LLY | VTIP | |
|---|---|---|
Market Cap | $1.04T | $73.20B |
Volume | 3,064,878 | 2,511,360 |
Sector | Health | — |
52-Week High | $1.28K | $50.46 |
52-Week Low | $799.57 | $48.38 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.46 with no change in the last session. The technical outlook is bearish based on moving averages, though oscillators signal bullish momentum with RSI levels in oversold territory. Recent news highlights its role as a hedge against inflation and rising rates, with institutional investors increasing positions. Key support is at $48, with resistance at $49.
The outlook for VTIP is supported by its design to mitigate inflation risk amid persistent price pressures, but it faces headwinds from Federal Reserve policy uncertainty. Investment appeal lies in its short-duration TIPS focus, reducing interest-rate sensitivity, while risks include potential inflation moderation and real yield volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
